Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.

@article{Buehler2010ComparisonOG,
  title={Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.},
  author={Patrick Buehler and Thomas Fischer and Philipp Wolf and Dorothee Gierschner and Wolfgang Schultze-Seemann and Ulrich Wetterauer and Ursula Els{\"a}sser-Beile},
  journal={Urologia internationalis},
  year={2010},
  volume={84 2},
  pages={203-11}
}
INTRODUCTION Androgen deprivation is the preferred treatment for disseminated prostate cancer. However, it mostly leads to the development of incurable androgen-independent disease. The aim of the present study was to compare gene expression changes that occur after treatment with either the antiandrogen bicalutamide or the 5-alpha-reductase inhibitors finasteride (MK906) and MK386. MATERIALS AND METHODS LNCaP cells of low passages were treated with MK906 and MK386 at 5 microM each or with… CONTINUE READING